DBV Technologies to Attend Upcoming Investor Conferences

MONTROUGE, France, May 20, 2016 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following investor events:

• Susanna Mesa, Senior Vice President, Strategy, will present at the UBS Global Healthcare Conference in New York, NY, on Monday, May 23, 2016 at 3:30 pm ET
• Susanna Mesa, Senior Vice President, Strategy, will present at the Barclays West Coast Biopharma Conference in Calistoga, CA, on Wednesday, June 1, 2016 at 1:30 pm PT.
• Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Senior Vice President, Strategy, will present at the Jefferies 2016 Healthcare Conference in New York, NY, on Tuesday, June 7, 2016, at 3:30 pm ET.

A live webcast of the Jefferies 2016 Healthcare Conference will be available on the Investor Relations section of the Company's website: http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV's website within 48 hours after the event.

About DBV Technologies

DBV Technologies developed Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

PDF Version http://hugin.info/156437/R/2013661/746310.pdf

HUG#2013661

You May Also Be Interested In

• Jersey Mike's launches IPO roadshow, targets NYSE listing as JMKE
• Good Employers Keep Choosing the Wrong PBM Because They Start With the Wrong Metrics
• My EU Pay to Diversify Client-Fund Safeguarding with BlackRock AAA-Rated Money Market Funds